3 news items
Coya Therapeutics Expands Sponsored Research Collaboration with Houston Methodist Research Institute Along with Funding from the Johnson Center for Cellular Therapeutics to Advance Regulatory T Cell Exosome Platform into the Clinic
COYA
20 Jun 24
of COYA 301 (LD IL-2) with other relevant drug products, following the innovative approach of COYA 302 (LD IL-2 + CTLA4-Ig) targeting multiple paths
EXCLUSIVE: Coya Therapeutics, Focused On Neurodegenerative Diseases Has Gained 70% Since IPO; CEO Highlights Efforts On Combination Therapy For Rare Diseases
BIIB
COYA
27 May 24
are developing an innovative therapeutic platform which has the potential to transform the treatment of neurodegenerative and autoimmune diseases
Coya Therapeutics Announces $5 Million Strategic Investment by the Alzheimer's Drug Discovery Foundation (ADDF)
COYA
20 May 24
302, is an innovative approach being developed to suppress neuroinflammation by targeting multiple inflammatory pathways," said Howard Fillit, M.D
- Prev
- 1
- Next